See more : Société Foncière Lyonnaise (FLY.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Geffen Residence & Renewal Ltd (GEFR.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geffen Residence & Renewal Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- SouthState Corporation (SSB) Income Statement Analysis – Financial Results
- Capricorn Systems Global Solutions Limited (CAPRICORN.BO) Income Statement Analysis – Financial Results
- Emkay Global Financial Services Limited (EMKAY.BO) Income Statement Analysis – Financial Results
- TPI Polene Power Public Company Limited (TPIPP-R.BK) Income Statement Analysis – Financial Results
- PT Charoen Pokphand Indonesia Tbk (PPOKF) Income Statement Analysis – Financial Results
Geffen Residence & Renewal Ltd (GEFR.TA)
About Geffen Residence & Renewal Ltd
Geffen Residence & Renewal Ltd engages in the cultivation, production, storage, marketing, and sale of medical cannabis in Israel. It owns pharmacies, which sell cosmetics, convenience, and toiletries, as well as pharmacy and natural products, such as marketing prescription drugs, over-the-counter drugs, natural products, and vitamins and supplements. The company also offers plasters and bandages; and thermometer and humidifiers. The company was formerly known as Cannomed Medical Cannabis Industries Ltd. The company was incorporated in 1999 and is based in Tel Aviv-Yafo, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 60.00K | 658.00K | 17.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 5.99M | 10.88M | 13.08M | 283.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 142.00K | -5.93M | -10.22M | 4.83M | -283.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -9,890.00% | -1,553.80% | 26.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.68M | 2.43M | 2.53M | 2.47M | 2.51M | 107.00K | 1.65M | 2.10M | 1.45M |
| Selling & Marketing | 193.00K | 283.00K | 508.00K | 487.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.87M | 2.71M | 3.04M | 2.96M | 2.51M | 107.00K | 1.65M | 2.10M | 1.45M |
| Other Expenses | 4.06M | -414.00K | -450.00K | -723.00K | 437.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.93M | 4.32M | 5.45M | 9.92M | 6.77M | 849.00K | 1.65M | 2.45M | 1.45M |
| Cost & Expenses | 6.93M | 10.32M | 16.33M | 23.01M | 7.05M | 849.00K | 1.65M | 2.45M | 1.45M |
| Interest Income | 159.00K | 290.00K | 60.00K | 9.00K | 0.00 | 0.00 | 200.00K | 1.32M | 0.00 |
| Interest Expense | 48.00K | 404.00K | 905.00K | 1.37M | 1.41M | 2.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 518.00K | 2.14M | 1.96M | 605.00K | 410.00K | 245.00K | 2.00K | -1.38M | -289.00K |
| EBITDA | -6.11M | -16.48M | -18.18M | -5.29M | -1.56M | -849.00K | -874.00K | -2.40M | -1.74M |
| EBITDA Ratio | -4,300.00% | -12,938.33% | -2,150.00% | -29.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.78M | -18.88M | -20.16M | -9.60M | -6.69M | -849.00K | -1.65M | -1.02M | -1.45M |
| Operating Income Ratio | -4,776.76% | -31,465.00% | -3,063.07% | -53.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 111.00K | -146.00K | -894.00K | -1.41M | -7.62M | 407.00K | -1.43M | 1.06M | 272.00K |
| Income Before Tax | -6.67M | -19.03M | -21.05M | -11.15M | -9.38M | -851.00K | -3.08M | 37.00K | -1.18M |
| Income Before Tax Ratio | -4,698.59% | -31,708.33% | -3,198.94% | -62.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -499.00K | 9.52M | 1.47M | -2.90M | -1.97M | -161.14K | 775.00K | 177.00K | 335.00K |
| Net Income | -6.91M | -20.08M | -13.43M | -8.81M | -9.38M | -851.00K | -3.08M | -140.00K | -1.52M |
| Net Income Ratio | -4,866.20% | -33,470.00% | -2,040.43% | -49.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.20 | -0.15 | -0.35 | -1.03 | -0.31 | -0.61 | -0.03 | -0.30 |
| EPS Diluted | -0.03 | -0.20 | -0.15 | -0.35 | -1.03 | -0.31 | -0.61 | -0.03 | -0.30 |
| Weighted Avg Shares Out | 251.19M | 99.39M | 88.04M | 24.93M | 9.14M | 2.71M | 5.02M | 5.02M | 5.02M |
| Weighted Avg Shares Out (Dil) | 215.64M | 99.39M | 88.04M | 24.93M | 9.14M | 2.71M | 5.02M | 5.02M | 5.02M |
Source: https://incomestatements.info
Category: Stock Reports